Articles tagged with Metastasis
Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.
Researchers at MD Anderson Cancer Center have identified disparities in end-of-life immunotherapy treatment, highlighting the need for further examination to ensure quality care. A new study also reveals a novel target to improve immunotherapy responses in KRAS-mutant lung cancer and strategies to manage immune-related toxicities.
Researchers found that cancer cells prevent surrounding cells from fighting tumors, but medication can reverse this process. Metastatic tumor cells retain cellular plasticity and change gene expression based on the neuroblastoma genetic subtype.
Researchers at MD Anderson Cancer Center have engineered a new model of aggressive renal cell carcinoma, highlighting molecular targets and genomic events that trigger chromosomal instability. The loss of interferon receptor genes plays a pivotal role in allowing cancer cells to become tolerant of chromosomal instability.
A preclinical study has uncovered the role of Y chromosome gene KDM5D in regulating anti-tumor immune responses and promoting metastasis in male patients with KRAS-mutated colorectal cancer. The study reveals that mutant KRAS drives upregulation of KDM5D, leading to reduced cell adhesion and immune recognition by the immune system.
A team of researchers at the University of Tennessee Health Science Center has received a $3.07 million grant from the National Cancer Institute to develop new drugs targeting microtubules for breast cancer treatment. The goal is to improve overall survival and quality of life for patients with metastatic breast cancer.
Researchers found that leukemia cells use messenger particles to navigate and release molecular cargo at distant sites, driving cancer metastasis. A potential therapeutic strategy involves targeting these particles with an antibody drug that blocks E-selectin activity.
Researchers found that morphine interacts with toll-like receptor 4 to contribute to increased bone loss and pain. Blocking TLR4 prevents these effects, suggesting a new target for reducing opioid side effects.
A patient with kidney cancer overcame several metastases with temsirolimus, leading researchers to identify key mutations that make this treatment effective. The study found that patients with USP9X mutations have altered autophagy and respond better to temsirolimus.
A study has identified a potential treatment target for prostate cancer that is resistant to hormone therapy, a protein modification involving TRAF4. The researchers found that TRAF4 promotes the spread of cancer and may be associated with a new treatment option for patients.
Researchers studied breast cancer cells that spread through the body and found a key mechanism driving their growth. The study reveals how cancer cells employ 'plasticity' to adopt properties promoting metastatic growth.
A team of researchers discovered a process that helps breast cancer cells implant themselves in certain places in the body, leading to poorer prognosis. Overproduction of NNMT is key to metastasis, producing excessive collagen that enables cancer cells to survive and adapt.
Researchers discovered that targeting specific blood vessel enzymes can enhance immunotherapy effectiveness and prevent breast cancer metastasis. By disabling the enzyme DNMT1 in blood vessels, doctors may bolster anti-tumor immune cells entry and increase patients' response to treatment.
A phase 2 trial found that immune checkpoint inhibitor pembrolizumab had a durable antitumor effect in 24 of 57 patients with metastatic brain cancer. The study achieved its primary endpoint, with median overall survival of 8 months and seven patients surviving longer than two years.
Scientists at Tohoku University discovered a novel approach to enhance the efficacy of immune checkpoint blockade and minimize associated side effects. Targeting tumor-positive lymph nodes with ICIs generates a robust anti-tumor response against local and systemic metastases.
Researchers presented findings on pembrolizumab for brain metastases, virtual mind-body interventions for post-treatment survival, and dynamic HER2-low status in triple negative breast cancer. The studies aim to improve treatments and outcomes for patients with cancer.
Scientists from Brigham and Women's Hospital have developed a new immuno-therapeutic approach using twin stem cells that can target brain metastatic melanomas. The therapy, which uses an engineered 'twin stem cell model,' activates the immune system to suppress tumor growth and prolong survival in representative preclinical models.
Researchers discovered that melanoma skin cancer cells adopt an efficient style of movement called rounded-amoeboid migration, which requires less energy than traditional cell movement. This process involves reshaping mitochondria to operate in a low-power mode, allowing cells to survive in stressful environments.
Researchers developed a drug treatment that inhibits YTHDF2, improving results of radiation therapy and preventing progression of distant metastasis. The treatment also prevents the "bad-scopal" effect, where radiation causes distant tumors to metastasize.
Researchers found that distant cancers alter liver function by inducing fat accumulation and inflammation in liver cells. The process involves secretion of extracellular vesicles containing fatty acids, which reprogram the liver to resemble fatty liver disease.
Researchers have discovered that HER3 plays a crucial role in promoting cell survival in metastatic colorectal and pancreatic cancer. The surrounding liver microenvironment activates HER3, making it an emerging therapeutic target for these types of cancer.
Researchers have found that craniospinal radiation can control metastasis in diffuse midline gliomas, leading to improved treatment options for patients. The study suggests that this approach may lead to long-term survival and potentially curative effects for these children.
Researchers from the UCLA Jonsson Comprehensive Cancer Center are presenting findings on combination therapies for breast cancer and a potential new treatment for patients with recurrent glioma. A phase 3 study evaluating vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation is also be...
Researchers found that GPR141 enhances cell migration and proliferation in breast cancer by activating the p-mTOR/p53 signaling pathway. Silencing GPR141 restores p53 expression and attenuates tumor growth, suggesting its role in regulating breast cancer progression and metastasis.
Researchers from Rice University and Baylor College of Medicine are developing a new 'glyco-immune' checkpoint inhibitor to train the immune system to target and kill breast cancer metastasis in bones. The therapy has shown promise in preliminary tests, including eradicating cancer in some animals.
Researchers at Dartmouth Cancer Center found that alternating estrogen stimulation and anti-estrogen therapy is an effective treatment for patients with metastatic or advanced ER+ breast cancer. The POLLY trial showed that 42% of patients experienced tumor stabilization, while no patients discontinued treatment due to side effects.
A recent meta-analysis shows that amino acid PET can accurately differentiate between recurrent brain metastases and treatment-related changes. This technology has the potential to reduce unnecessary invasive procedures and overtreatment in patients with cancer.
A recent study published in PNAS reveals that succinate plays a critical role in enhancing cancer cell plasticity and identifies PLOD2 as a regulator of succinate during breast cancer progression. Targeting PLOD2 may be a promising strategy to suppress breast cancer metastasis and drug resistance.
Researchers found that fatty liver cells secrete proteins and genetic material that promote the spread of colorectal cancer to the liver. This condition is likely underdiagnosed, affecting over 40% of patients with colorectal cancer, according to a new study published in Cell Metabolism.
Scientists have created a new way to image and track macrophages in the body using ultrasound-enhanced immune cells. This method has potential for early cancer detection and monitoring of therapeutic efficacy. The technique involves attaching microbubbles to macrophages, allowing for high-resolution tracking images.
A new study from Duke University identifies 1,500 genes essential for invasive cell behavior in C. elegans worms. The researchers created a 'parts list' of these genes and proteins, which may help identify effective ways to stop cancer's spread.
Moffitt researchers develop CAR T cells that target prostate cancer biomarker PSCA, killing cancer cells and preserving bone health. Zoledronate treatment enhances antitumor activity with minimal toxicity.
A deep learning model has been developed to classify cancer cells into distinct types, enabling accurate prediction of metastatic potential. The tool achieves high accuracy and is simple to use, making it a promising solution for medical practitioners.
Researchers have identified ATAD3A as a molecular determinant that favors the development of head and neck cancer. The protein is involved in various cellular processes, including energy metabolism and apoptosis. Targeting ATAD3A could offer a novel approach to developing effective anti-cancer therapeutics.
A study identified a protein, UBE2C, present in brain metastases associated with worse disease prognosis. Researchers found that high levels of UBE2C increase the spread of tumor cells in the central nervous system.
Researchers analyzed genetic changes in organs of recently deceased patients with metastatic cutaneous melanoma to understand how the disease spreads and evolves. They found that cancer cells take advantage of specific organ environments, pointing to the need for distinct treatment approaches.
Researchers at Tokyo Medical and Dental University identify a novel focal adhesion remodeling process that strengthens cell-matrix adhesion in response to genotoxic stress. This mechanism involves the replacement of FAK with FRNK, leading to increased firm cell attachment.
The guideline provides guidance on definitive local therapy options for non-small cell lung cancer with limited extracranial metastases. It emphasizes the need for a patient-centered, multidisciplinary approach to treatment decisions.
Researchers found that necroptosis promotes metastasis in breast cancer models, and blocking it leads to inhibition of metastasis. Necroptosis may be a key factor in tumor progression, and targeting its regulators could be critical for mitigating metastasis.
A new PSMA PET scoring system, the tumor-to-salivary gland ratio (PSG score), can predict patient response to <sup> 177 </sup> Lu-PSMA therapy. Patients with high PSG scores had longer PSA progression-free survival and overall survival rates.
Scientists discovered that deleting a protein called sphingosine kinase 2 (SphK2) reprograms the tumor microenvironment, decreasing S1P levels and increasing p53 tumor suppressor gene accumulation. This creates an inhospitable environment for aggressive breast tumors.
Research discovers how cancer cells evade immune system detection and metastasize in the body. Pre-metastatic cells and exhausted CD8+ cells are identified as key players in this process. The study explores ways to target these pathways and activate immune responses to block metastasis.
A new study reveals that the HOXB13 protein regulates PSMA expression, even when the androgen receptor is absent, and identifies amino acids that are upregulated in low-PSMA tumors. This complex system of PSMA control has multiple subtypes, suggesting optimally targeted therapies.
Researchers propose a new method of clustering colorectal cancer patients using differential presence of exons (DPE) sequencing, which can provide valuable information on CRC progression and response to therapy. This analysis may also reduce costs and time required for staging CRC patients.
Researchers discuss cortactin's impact on cancer progression by modulating the Wnt5a/ROR1 signaling pathway. Cortactin expression is found in various cancers, including breast and chronic lymphocytic leukemia, suggesting its potential role in promoting metastasis.
Researchers used microfluidic devices to track what happens to cancer cells as they migrate and take root in the brain. They found that Dkk-1 triggers cancer cell migration, and reducing its levels near tumor cells may disrupt crosstalk between brain niche cells and cancer cells.
Researchers propose conjugating a cell-penetrating peptide to oxaliplatin to overcome chemotherapy resistance in colorectal cancer. The new approach reduces platinum accumulation in tumour microenvironment and healthy tissues.
Researchers at the University of Texas M. D. Anderson Cancer Center have developed a novel approach to administer intrathecal and intravenous immunotherapy to treat leptomeningeal disease (LMD) in melanoma patients, showing promising results in improving survival rates and quality of life for some patients.
A team of scientists at Memorial Sloan Kettering Cancer Center identified the STING cellular signaling pathway as a key player in keeping dormant cancer cells from progressing into aggressive tumors. Drugs that activate STING could help prevent the spread of cancer to new sites, a process known as metastasis.
Cancer cells have been found to employ a strategy to evade the immune system's killer T cells by interacting with myeloid cells and suppressing type 1 interferon production. This natural pathway is crucial for recruiting killer T cells to combat cancer spread. Researchers hope to develop new therapeutic approaches, such as forcing tumo...
The circadian rhythm governs most cellular functions implicated in cancer progression, making it an opportunity to intervene in the most timely and effective way. Leveraging this information, chronotherapy holds promise as a valuable alternative treatment option.
Researchers found that immunotherapy can activate tumor-fighting T cells in nearby lymph nodes, potentially boosting efficacy against solid tumors. The study suggests leaving lymph nodes intact until after immunotherapy could improve treatment outcomes for patients with head and neck cancers.
A recent study analyzed 7,301 metastatic breast cancer patients with MTAP loss, revealing younger age, higher TNBC cases, and BRCA1 mutations. The findings also suggest potential therapeutic agents targeting PRMT5 and MTA2 in MTAP-deficient cancers.
Researchers at City University of Hong Kong identified lysyl hydroxylase 1 (LH1) as a key factor in promoting confined migration of liver and pancreatic cancer cells. The study found that LH1 promotes metastasis by stabilizing Septin2, which enhances the actin network.
Researchers identified a way to treat surrounding breast tumors that have spread to bone, making them vulnerable to the immune system's attack. Boosting T cells and macrophages eliminated metastatic breast tumors in mice, suggesting a new approach for treating bone-spreading breast cancers.
Researchers have identified mitochondrial signaling pathways as critical organelles that promote tumorigenesis and metastasis. In particular, the integrated stress response is found to engage with mitochondria to drive tumor growth, highlighting a new paradigm for understanding aggressive prostate cancer progression.
Researchers have identified a key cause of metastasis from aggressive brain cancer in children and found a potential new therapy. Medulloblastoma cells hijack neurodevelopmental signaling pathways to promote tumor cell spreading. Targeting these pathways with a drug called dasatinib has shown promise in killing metastatic tumors.
Researchers discovered a new personalized immunotherapy combination that treats aggressive forms of advanced prostate cancer. By blocking PD-1-expressing macrophages and Wnt/β-catenin pathway activation, the therapy significantly improves response rates in PTEN-deficient cancers.
Researchers have identified a new marker that indicates when skin cancer cells are preparing to metastasise. The study shows that tumour cells alter their metabolism to feed on bad cholesterol molecules, allowing them to survive migration and proliferation in other organs.
Researchers have identified markers associated with an increased risk of metastasis in patients with metastatic pheochromocytoma, allowing for personalized clinical management. The study also identifies patients who could benefit from immunotherapy treatments, paving the way for potential new therapies.